Biofrontera, Inc. (BFRI)

Over the past six months, Biofrontera's stock has been influenced by several key events. In May 2025, the company reported a revenue increase, finalized patient enrollment in a Phase 3 clinical trial for Ameluz®, and received a patent approval. In August 2025, Biofrontera reported strong financial results, restructured its relationship with Biofrontera AG, and secured additional funding. In September 2025, Benchmark Co. maintained a Buy rating on Biofrontera. In November 2025, the company reported a revenue decrease due to prior-year advance purchases, finalized the purchase of U.S. Ameluz and RhodoLED assets, received the final tranche of financing, and sold its Xepi® license. The stock price as of November 19, 2025, was $0.81 per share.

Biofrontera anticipates quarterly seasonality in demand, with strong fourth-quarter revenues. The Q3 2025 revenue decline was attributed to customers making advance purchases in Q3 2024 ahead of a price increase. The company expects substantial Q4 revenue growth as the effects of the prior year's price increase normalize. The existing base of approximately 750 installed RhodoLED lamps is noted to support recurring demand for Ameluz gel.

Biofrontera, Inc. is a U.S.-based biopharmaceutical company specializing in dermatological treatments, particularly for sun exposure-related conditions and bacterial skin infections. Its main product is Ameluz®, used with the BF-RhodoLED® lamp for photodynamic therapy of actinic keratoses. The company previously commercialized Xepi® for impetigo but sold its U.S. license in November 2025.

Biofrontera, Inc. primarily operates in the United States and is headquartered in Woburn, Massachusetts.

Biofrontera's brand reputation has been influenced by strong Q2 2025 financial results, the acquisition of U.S. IP rights for key products, securing additional funding, and progress in clinical trials. Conversely, a Q3 2025 revenue decline and increased net loss could affect investor sentiment. The company emphasizes its commitment to advancing treatment options and patient care.

Biofrontera, Inc. has 24 institutional owners and shareholders, owning 10.08% of the stock. Major institutional owners include Rosalind Advisors, Inc., and AIGH Capital Management LLC. Following its IPO, Biofrontera AG held a significant portion of the stock, and as part of an asset purchase in August 2025, Biofrontera AG received a 10% post-money equity stake.